Objective: Consensus guidelines recommend that intensive care unit (ICU) patients with blood glucose (BG) levels >180 mg/dL receive continuous intravenous insulin (CII). The effectiveness of CII at controlling BG levels among patients who are eating relative to those who are eating nothing by mouth (nil per os; NPO) has not been described. Methods: We conducted a retrospective cohort study of 260 adult patients (156 eating, 104 NPO) admitted to an ICU between January 1, 2014, and December 31, 2014, who received CII. Patients were excluded for a diagnosis of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic syndrome, admission to an obstetrics service, or receiving continuous enteral or parenteral nutrition. Results: Among 22 baseline characteristics, the proportion of patients receiving glucocorticoid treatment (GCTx) (17.3% eating, 37.5% NPO; P<.001) and APACHE II score (15.0 ± 7.5 eating, 17.9 ± 7.9 NPO; P = .004) were significantly different between eating and NPO patients. There was no significant difference in the primary outcome of patient-day weighted mean BG overall (153 ± 8 mg/dL eating, 156 ± 7 mg/dL NPO; P = .73), or day-by-day BG (P = .37) adjusted for GCTx and APACHE score. Surprisingly, there was a significant difference in the distribution of BG values, with eating patients having a higher percentage of BG readings in the recommended range of 140 to 180 mg/dL. However, eating patients showed greater glucose variability (coefficient of variation 23.1 ± 1.0 eating, 21.2 ± 1.0 NPO; P = .034). Conclusion: Eating may not adversely affect BG levels of ICU patients receiving CII. Whether or not prandial insulin improves glycemic control in this setting should be studied. Abbreviations: BG = blood glucose; CII = continuous insulin infusion; CV = coefficient of variation; HbA1c = hemoglobin A1c; ICU = intensive care unit; NPO = nil per os; PDWMBG = patient day weighted mean blood glucose.
Objective: Consensus guidelines recommend that intensive care unit (ICU) patients with blood glucose (BG) levels >180 mg/dL receive continuous intravenous insulin (CII). The effectiveness of CII at controlling BG levels among patients who are eating relative to those who are eating nothing by mouth (nil per os; NPO) has not been described. Methods: We conducted a retrospective cohort study of 260 adult patients (156 eating, 104 NPO) admitted to an ICU between January 1, 2014, and December 31, 2014, who received CII. Patients were excluded for a diagnosis of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic syndrome, admission to an obstetrics service, or receiving continuous enteral or parenteral nutrition. Results: Among 22 baseline characteristics, the proportion of patients receiving glucocorticoid treatment (GCTx) (17.3% eating, 37.5% NPO; P<.001) and APACHE II score (15.0 ± 7.5 eating, 17.9 ± 7.9 NPO; P = .004) were significantly different between eating and NPO patients. There was no significant difference in the primary outcome of patient-day weighted mean BG overall (153 ± 8 mg/dL eating, 156 ± 7 mg/dL NPO; P = .73), or day-by-day BG (P = .37) adjusted for GCTx and APACHE score. Surprisingly, there was a significant difference in the distribution of BG values, with eating patients having a higher percentage of BG readings in the recommended range of 140 to 180 mg/dL. However, eating patients showed greater glucose variability (coefficient of variation 23.1 ± 1.0 eating, 21.2 ± 1.0 NPO; P = .034). Conclusion: Eating may not adversely affect BG levels of ICU patients receiving CII. Whether or not prandial insulin improves glycemic control in this setting should be studied. Abbreviations: BG = blood glucose; CII = continuous insulin infusion; CV = coefficient of variation; HbA1c = hemoglobin A1c; ICU = intensive care unit; NPO = nil per os; PDWMBG = patient day weighted mean blood glucose.
Authors: Miguel Munoz; Peter Pronovost; Joanne Dintzis; Theresa Kemmerer; Nae-Yuh Wang; Yi-Ting Chang; Leigh Efird; Sean M Berenholtz; Sherita Hill Golden Journal: Jt Comm J Qual Patient Saf Date: 2012-05
Authors: Mark P Plummer; Rinaldo Bellomo; Caroline E Cousins; Christopher E Annink; Krishnaswamy Sundararajan; Benjamin A J Reddi; John P Raj; Marianne J Chapman; Michael Horowitz; Adam M Deane Journal: Intensive Care Med Date: 2014-04-24 Impact factor: 17.440
Authors: Dawn Smiley; Mary Rhee; Limin Peng; Laurian Roediger; Patrick Mulligan; Lewis Satterwhite; Patrick Bowen; Guillermo E Umpierrez Journal: J Hosp Med Date: 2010-04 Impact factor: 2.960
Authors: Shilpa Shetty; Silvio E Inzucchi; Philip A Goldberg; Dawn Cooper; Mark D Siegel; Shyoko Honiden Journal: Endocr Pract Date: 2012 May-Jun Impact factor: 3.443
Authors: Judith Jacobi; Nicholas Bircher; James Krinsley; Michael Agus; Susan S Braithwaite; Clifford Deutschman; Amado X Freire; Douglas Geehan; Benjamin Kohl; Stanley A Nasraway; Mark Rigby; Karen Sands; Lynn Schallom; Beth Taylor; Guillermo Umpierrez; John Mazuski; Holger Schunemann Journal: Crit Care Med Date: 2012-12 Impact factor: 7.598
Authors: Simon Finfer; Bette Liu; Dean R Chittock; Robyn Norton; John A Myburgh; Colin McArthur; Imogen Mitchell; Denise Foster; Vinay Dhingra; William R Henderson; Juan J Ronco; Rinaldo Bellomo; Deborah Cook; Ellen McDonald; Peter Dodek; Paul C Hébert; Daren K Heyland; Bruce G Robinson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez Journal: Diabetes Care Date: 2009-05-08 Impact factor: 19.112